Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + trastuzumab + MM-111
- Development stage
- Phase 1
- Lead developer
- Merrimack Pharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination therapy consisting of docetaxel, trastuzumab, and MM-111. Docetaxel is a taxane-class small molecule chemotherapeutic that inhibits cell division by stabilizing microtubules. Trastuzumab is a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), used primarily in HER2-positive breast cancer; it works by inhibiting HER2 signaling and mediating antibody-dependent cellular cytotoxicity (ADCC). MM-111 is a bispecific monoclonal antibody designed to target both HER2 and heregulin/HER3 signaling pathways, aiming to overcome resistance mechanisms in HER2-positive cancers. This combination has been investigated for synergistic anti-tumor activity in patients with advanced or metastatic HER2-positive breast cancer.
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB3 (Erb-b2 receptor tyrosine kinase 3)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on docetaxel + trastuzumab + MM-111.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + trastuzumab + MM-111.